Reported 1 day ago
Guggenheim has increased its price target for Savara Inc. (NASDAQ:SVRA) to $11 from $8, maintaining a Buy rating after a 16% stock rally this year. The upgrade is attributed to positive developments including alignment with the FDA on a Biologics License Application and the switch to Fujifilm Diosynth as the primary drug manufacturer, which may enhance production capabilities for treating autoimmune pulmonary alveolar proteinosis.
Source: YAHOO